Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major depressive disorder (MDD). However, non-response is common, often necessitating combination strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients with SSRI-resistant MDD.
Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study / De Berardis, D., Fornaro, M., Anastasia, A., Vellante, F., Olivieri, L., Rapini, G., Serroni, N., Orsolini, L., Valchera, A., Carano, A., Tomasetti, C., Ventriglio, A., Bustini, M., Pompili, M., Serafini, G., Perna, G., Iasevoli, F., Martinotti, G., Di Giannantonio, M.. - In: REVISTA BRASILEIRA DE PSIQUIATRIA. - ISSN 1516-4446. - (2020). [10.1590/1516-4446-2019-0690]
Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study
Fornaro, Michele;Anastasia, Annalisa;Tomasetti, Carmine;Iasevoli, Felice;
2020
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major depressive disorder (MDD). However, non-response is common, often necessitating combination strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients with SSRI-resistant MDD.| File | Dimensione | Formato | |
|---|---|---|---|
|
1516-4446-rbp-1516444620190690.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
124.91 kB
Formato
Adobe PDF
|
124.91 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
